Peptide Atlas · Peptide

Exenatide

Exenatide (exendin-4) is an incretin mimetic studied for glycemic control in type 2 diabetes.

established

provisional
PubChem 45588096
3 citations
0 discussions
0 followers
AC2993
Bydureon
Byetta
Exendin-4

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- established
  Claim: 30-week randomized trial in metformin-treated type 2 diabetes standing
- resolved
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD
pmid 15855572
- established
  Claim: EXSCEL cardiovascular outcomes trial standing
- resolved
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group
pmid 28910237
- preclinical
  Claim: Exendin-4 increases beta-cell mass in diabetic rats standing
- resolved
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu G, Stoffers DA, Habener JF, Bonner-Weir S
pmid 10580413

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.